ConcertAI & NeoGenomics Launch CTO-H for Hematology Research
What You Should Know:
– ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.
– CTO-H provides a research data solution that is…
Continue Reading